<SEC-DOCUMENT>0001213900-22-021747.txt : 20220427
<SEC-HEADER>0001213900-22-021747.hdr.sgml : 20220427
<ACCEPTANCE-DATETIME>20220427060417
ACCESSION NUMBER:		0001213900-22-021747
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20220427
FILED AS OF DATE:		20220427
DATE AS OF CHANGE:		20220427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NLS Pharmaceutics Ltd.
		CENTRAL INDEX KEY:			0001783036
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39957
		FILM NUMBER:		22856141

	BUSINESS ADDRESS:	
		STREET 1:		THE CIRCLE 6
		STREET 2:		8058
		CITY:			ZURICH
		STATE:			V8
		ZIP:			CH-6370
		BUSINESS PHONE:		41-41-618-80-00

	MAIL ADDRESS:	
		STREET 1:		THE CIRCLE 6
		STREET 2:		8058
		CITY:			ZURICH
		STATE:			V8
		ZIP:			CH-6370
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea158916-6k_nlspharm.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of April 2022 (Report No. 5)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: 001-39957</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>NLS PHARMACEUTICS LTD.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Circle 6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>8058 Zurich, Switzerland</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulations S-T Rule 101(b)(1):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulations S-T Rule 101(b)(7):_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On April 26, 2022, NLS
Pharmaceutics Ltd., or the Registrant, issued a press release titled: &ldquo;NLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million
Registered Direct Offering.&rdquo; A copy of this press release is furnished herewith as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The press release furnished
as Exhibit 99.1 to this report is incorporated by reference into the Registrant&rsquo;s Registration Statement on Form F-3 (File No. 333-262489),
filed with Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not
superseded by documents or reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 8%; border-bottom: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit Number</B></P></TD>
    <TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 91%; border-bottom: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description of Document</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><A HREF="ea158916ex99-1_nlspharm.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release titled: &ldquo;NLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million Registered Direct Offering.&rdquo;</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">1</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NLS Pharmaceutics Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: April 27, 2022</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Alexander Zwyer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexander Zwyer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">2</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea158916ex99-1_nlspharm.htm
<DESCRIPTION>PRESS RELEASE TITLED: "NLS PHARMACEUTICS LTD. ANNOUNCES CLOSING OF US$4.4 MILLION REGISTERED DIRECT OFFERING."
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: left"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NLS Pharmaceutics Ltd. Announces Closing of
US$4.4 Million Registered Direct Offering </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ZURICH, SWITZERLAND / ACCESSWIRE / April 26, 2022
/ NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (&quot;NLS&quot; or the &quot;Company&quot;), a Swiss clinical-stage biopharmaceutical
company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorder,
today announced the closing of its previously announced registered direct offering with health-care focused institutional investors alongside
participation from the Company's Chairman of the Board of Directors, Ronald Hafner, for the purchase and sale of 4,200,000 of the Company's
common shares (or common share equivalents) at a purchase price of $1.04 per common share (or common share equivalent).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in a concurrent private placement,
the Company issued to the investors warrants to purchase up to 3,150,000 common shares. The warrants have an exercise price of $1.04 per
common share, are exercisable six months following the date of issuance and expire 5 years following the initial exercise date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A.G.P./Alliance Global Partners&nbsp;acted as
sole placement agent for the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The gross
proceeds to the Company from this offering are approximately US$4.4 million, before deducting the placement agent's fees and other offering
expenses payable by the Company. The Company intends to use the net proceeds from this offering, together with its existing cash, to fund
the ongoing development of its lead product, Quilience&reg; (Mazindol ER) for the treatment of narcolepsy, to support business development
and licensing activities, and for general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The common shares (or common share equivalents)
described above are being offered by the Company pursuant to an effective &quot;shelf&quot; registration statement on Form F-3, (File
No. 333-262489), including an accompanying prospectus, previously filed with, and declared effective by, the U.S. Securities and Exchange
Commission (the &quot;SEC&quot;) under the Securities Act of 1933 on February 11, 2022. A final prospectus supplement describing the terms
of the proposed offering has been filed with the SEC and is available on the SEC's website located at http://www.sec.gov. Electronic copies
of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New
York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants described above were offered and
sold in the concurrent private placement in the United States pursuant to the exemption from securities registration afforded by Section
4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 of Regulation D as promulgated by the SEC. The securities sold in such
private placement have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and accordingly
may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements.
The Company has agreed to file a registration statement with the SEC covering the resale of the common shares issuable upon the exercise
of the common warrants issued in the concurrent private placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release shall not constitute an offer
to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><IMG SRC="image_002.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About NLS Pharmaceutics Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NLS Pharmaceutics Ltd. is a Swiss clinical-stage
biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to
treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience&reg;, is a proprietary extended-release
formulation of Mazindol (Mazindol ER) and is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders
such as idiopathic hypersomnia (IH). Mazindol is a triple monoamine reuptake inhibitor and partial Orexin-2 Receptor agonist, which was
used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. A Phase 2a clinical trial evaluating Quilience&reg;
in adult subjects suffering from narcolepsy is currently ongoing in the United States. Previously, NLS successfully completed a Phase
2 study in the U.S. evaluating Nolazol&reg; (Mazindol Controlled-Release) in adult subjects suffering from ADHD. The study met all primary
and secondary endpoints and Nolazol&reg; was well-tolerated. Quilience&reg; has received Orphan Drug Designations both in the U.S. and
in Europe for the treatment of narcolepsy. Up to 1/3 of narcoleptic patients are also diagnosed with ADHD. NLS has announced that it plans
to enable patients diagnosed with IH to access treatment with Quilience&reg; through an Early Access Program (EAP). EAPs have great potential
to benefit all stakeholders involved, from the patient who receives the medicine early, to the pharmaceutical company who provides it.
Although EAPs can represent a significant undertaking, companies who invest in them can see considerable benefit in terms of launch preparedness,
relationship building and market penetration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Safe Harbor Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains express or implied
forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS is using forward-looking statements when it discusses
the intended use of proceeds. These forward-looking statements and their implications are based on the current expectations of the management
of NLS only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from
those described in the forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles
in launching and/or successfully completing its clinical trials; NLS' products may not be approved by regulatory agencies; NLS' technology
may not be validated as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain
or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop
with NLS' process; NLS' products may wind up being more expensive than it anticipates; results in the laboratory may not translate to
equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials;
NLS' patents may not be sufficient; NLS' products may harm recipients; changes in legislation may adversely impact NLS; inability to timely
develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition,
which could cause the actual results or performance of NLS to differ materially from those contemplated in such forward-looking statements.
Except as otherwise required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information
about the risks and uncertainties affecting NLS is contained under the heading &quot;Risk Factors&quot; in NLS' annual report on Form
20-F for the year ended December 31, 2021 filed with the SEC, which is available on the SEC's website, www.sec.gov, and in subsequent
filings made by NLS with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="image_003.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alex Zwyer, CEO: +41 44 512 21 50</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investor Relations Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cindy Rizzo: +1 908-229-7050</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Media Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pascal Nigen: +1 917-385-2160</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alpha Bronze, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">www.nlspharmaceutics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SOURCE: NLS Pharmaceutics AG</B></P>
<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; text-align: left"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !! /H# 2(  A$! Q$!_\0
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MJN ,C'J<Y]JTM/\ !N@WUW;>(?L<L4LZK<_9W;Y%8C=R,=<]NGM72W\ GLY
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(@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !! /H# 2(  A$! Q$!_\0
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MJN ,C'J<Y]JTM/\ !N@WUW;>(?L<L4LZK<_9W;Y%8C=R,=<]NGM72W\ GLY
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(@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !! /H# 2(  A$! Q$!_\0
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MJN ,C'J<Y]JTM/\ !N@WUW;>(?L<L4LZK<_9W;Y%8C=R,=<]NGM72W\ GLY
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(@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
